Protocol No
AZ-D822GC00001-TRAVERSE
Phase
II
Summary
This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Description
This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Status
SRC APPROVAL
Categories
ClinicalTrials.gov